Stonegate Capital Partners has updated its coverage on Incannex Healthcare Inc. $(IXHL)$ for the third quarter of fiscal year 2025. The company reported a decrease in R&D expenses to $2.74M and SG&A expenses to $2.27M, resulting in a reduced net loss of $3.97M. Cash and cash equivalents increased to $6.7M due to recent financing activities. Incannex will issue ~$24.7M worth of shares to repurchase all outstanding Series A Warrants. More details can be found at newsfilecorp.com/release/167783.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 253743) on May 28, 2025, and is solely responsible for the information contained therein.
Comments